VivoSeq
Oncology

Relapsed/refractory Multiple Myeloma

14

Pipeline Programs↗

8

Active Trials↗

8

Companies Involved↗

Relapsed/Refractory Multiple Myeloma is an emerging landscape with 14 programs across 8 companies. The most active players are Roche, Johnson & Johnson, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

4 programs

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3H

Hangzhou Sumgen Biotech Co., Ltd.

3 programs

Phase 3Regeneron logo

Regeneron

2 programs

PreclinicalAstraZeneca logo

AstraZeneca

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

12programs
Small molecule650%
Monoclonal antibody542%
Cell therapy18%

Modality classified for 80% of 15 pipeline programs.

Analysis

Trial Status

9

clinical trials

Recruiting7 · 78%
Completed1 · 11%
Active, not recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 for Injection in Patients With Relapsed/Refractory Multiple Myeloma
Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Preclinical·NCT07454187·40 enrolled
A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 3·NCT06508983·360 enrolled
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Recruiting·BBeOne Medicines·Preclinical·NCT04973605·246 enrolled
A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT05160584·300 enrolled
An Open-Label, Multicenter, Phase Ia/b Study Evaluating the Safety and Pharmacokinetics of RO7851624 in Patients With Relapsed/Refractory Multiple Myeloma
Recruiting·Roche logoRoche·Phase 1·NCT07558915·160 enrolled
A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)
Recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT05850234·182 enrolled
A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma
Recruiting·Regeneron logoRegeneron·Preclinical·NCT06669247·186 enrolled
A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibition for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT05338775·74 enrolled
Analysis of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Receiving Pomalidomide-Containing and Non-Pomalidomide-Containing Regimens in the Real World: A OneOncology United States Database Study
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT07689006·341 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)